Meanwhile, Astex Pharmaceuticals has reported the successful application of 2 drug precursors to degrade 2 cancer targets, bromine domain protein 4 (BRD4) and ERK1/2, utilizing IEDDA click chemistry to form a hetero-bifunctional molecule in cells (Fig. 21B) [164]. This evidence concerns the gene BRD4 and cancer.